Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per valutare l'efficacia e la sicurezza del bimekizumab nei partecipanti allo studio con idrosadenite suppurativa da moderata a grave (BE HEARD I)

1 ottobre 2026 aggiornato da: UCB Biopharma SRL

Uno studio di fase 3, randomizzato, in doppio cieco, controllato con placebo, multicentrico che valuta l'efficacia e la sicurezza di bimekizumab nei partecipanti allo studio con idrosadenite suppurativa da moderata a grave

The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

505

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Campbelltown, Australia
        • Hs0003 30015
      • Carlton, Australia
        • Hs0003 30016
      • East Melbourne, Australia
        • Hs0003 30011
      • Kogarah, Australia
        • Hs0003 30017
      • Woolloongabba, Australia
        • Hs0003 30012
      • Brussels, Belgio
        • Hs0003 40004
      • Brussels, Belgio
        • Hs0003 40121
      • Leuven, Belgio
        • Hs0003 40002
      • Liège, Belgio
        • Hs0003 40060
      • Barrie, Canada
        • Hs0003 50233
      • Richmond Hill, Canada
        • Hs0003 50190
      • Saskatoon, Canada
        • Hs0003 50192
      • St. John's, Canada
        • Hs0003 50173
      • Surrey, Canada
        • Hs0003 50133
      • Aarhus N, Danimarca
        • Hs0003 40127
      • Amiens, Francia
        • Hs0003 40197
      • Angers, Francia
        • Hs0003 40342
      • Le Mans, Francia
        • Hs0003 40355
      • Nice, Francia
        • Hs0003 40132
      • Rouen, Francia
        • Hs0003 40318
      • Saint-Mandé, Francia
        • Hs0003 40246
      • Toulon, Francia
        • Hs0003 40285
      • Berlin, Germania
        • Hs0003 40325
      • Bochum, Germania
        • Hs0003 40248
      • Bonn, Germania
        • Hs0003 40327
      • Darmstadt, Germania
        • Hs0003 40288
      • Dresden, Germania
        • Hs0003 40324
      • Kiel, Germania
        • Hs0003 40249
      • Magdeburg, Germania
        • Hs0003 40357
      • Mainz, Germania
        • Hs0003 40174
      • München, Germania
        • Hs0003 40323
      • Münster, Germania
        • Hs0003 40177
      • Athens, Grecia
        • Hs0003 40251
      • Athens, Grecia
        • Hs0003 40253
      • Thessaloniki, Grecia
        • Hs0003 40252
      • Haifa, Israele
        • Hs0003 20089
      • Tel Aviv, Israele
        • Hs0003 20088
      • Catania, Italia
        • Hs0003 40261
      • Roma, Italia
        • Hs0003 40257
      • Roma, Italia
        • Hs0003 40263
      • Rozzano, Italia
        • Hs0003 40258
      • Terracina, Italia
        • Hs0003 40331
      • Torino, Italia
        • Hs0003 40330
      • Trondheim, Norvegia
        • Hs0003 40332
      • Breda, Olanda
        • Hs0003 40351
      • Groningen, Olanda
        • Hs0003 40292
      • Rotterdam, Olanda
        • Hs0003 40264
      • Badalona, Spagna
        • Hs0003 40266
      • Las Palmas de Gran Canaria, Spagna
        • Hs0003 40294
      • Pontevedra, Spagna
        • Hs0003 40295
      • Seville, Spagna
        • Hs0003 40049
      • Valencia, Spagna
        • Hs0003 40230
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • Hs0003 50140
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85006
        • Hs0003 50175
    • California
      • Los Angeles, California, Stati Uniti, 90045
        • Hs0003 50161
      • San Diego, California, Stati Uniti, 92123
        • Hs0003 50220
    • Florida
      • North Miami Beach, Florida, Stati Uniti, 33162-4708
        • Hs0003 50205
      • Ormond Beach, Florida, Stati Uniti, 32174
        • Hs0003 50153
      • Tampa, Florida, Stati Uniti, 33613
        • Hs0003 50141
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30309
        • Hs0003 50210
      • Watkinsville, Georgia, Stati Uniti, 30677
        • Hs0003 50280
    • Kentucky
      • Murray, Kentucky, Stati Uniti, 42071
        • Hs0003 50425
    • Massachusetts
      • Beverly, Massachusetts, Stati Uniti, 01915
        • Hs0003 50198
      • Boston, Massachusetts, Stati Uniti, 02215
        • Hs0003 50146
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68144
        • Hs0003 50194
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89148
        • Hs0003 50208
    • New Jersey
      • East Windsor, New Jersey, Stati Uniti, 08520
        • Hs0003 50137
    • New York
      • New York, New York, Stati Uniti, 10003
        • Hs0003 50235
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27516
        • Hs0003 50151
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45219
        • Hs0003 50177
      • Columbus, Ohio, Stati Uniti, 43213
        • Hs0003 50138
    • Oklahoma
      • Tulsa, Oklahoma, Stati Uniti, 74135
        • Hs0003 50204
    • Pennsylvania
      • Hershey, Pennsylvania, Stati Uniti, 17033
        • Hs0003 50147
    • Rhode Island
      • Johnston, Rhode Island, Stati Uniti, 02919
        • Hs0003 50008
      • Providence, Rhode Island, Stati Uniti, 02903
        • Hs0003 50180
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37215
        • Hs0003 50142
    • Texas
      • Arlington, Texas, Stati Uniti, 76011
        • Hs0003 50201
      • Dallas, Texas, Stati Uniti, 75246
        • Hs0003 50166
      • San Antonio, Texas, Stati Uniti, 78213
        • Hs0003 50149
    • Washington
      • Seattle, Washington, Stati Uniti, 98101
        • Hs0003 50270
      • Bern, Svizzera
        • Hs0003 40337
      • Geneva, Svizzera
        • Hs0003 40406
      • Ankara, Turchia (Türkiye)
        • Hs0003 40053
      • Antalya, Turchia (Türkiye)
        • Hs0003 40270
      • Gaziantep, Turchia (Türkiye)
        • Hs0003 40273
      • Istanbul, Turchia (Türkiye)
        • Hs0003 40050
      • Istanbul, Turchia (Türkiye)
        • Hs0003 40272
      • Izmir, Turchia (Türkiye)
        • Hs0003 40271

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Participant must be at least 18 years of age, at the time of signing the informed consent. If a study participant is under the local age of consent and is at least 18 years of age, written informed consent will be obtained from both the study participant and the legal representative

  • Study participants must have a diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 6 months prior to the Baseline visit

  • Study participant must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla), 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits

  • Study participant must have moderate to severe HS defined as a total of ≥5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits

  • Study participant must have had an inadequate response to a course of a systemic antibiotic for treatment of HS as assessed by the Investigator through study participant interview and review of medical history

  • A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP) OR
    2. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 20 weeks after the last dose of investigational medicinal product (IMP)

Exclusion Criteria:

  • Draining tunnel count of >20 at the Baseline Visit
  • Any other active skin disease or condition (eg, bacterial cellulitis, candida intertrigo, extensive condyloma) that may, in the opinion of the Investigator, interfere with the assessment of hidradenitis suppurativa (HS)
  • Study participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease (IBD)
  • Primary immunosuppressive condition, including taking immunosuppressive therapy following an organ transplant, or has had a splenectomy
  • Female who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP)
  • Active infection or history of certain infection(s)
  • Active tuberculosis (TB) infection, latent TB infection, high risk of exposure to TB infection, current or history of nontuberculous mycobacterium (NTM) infection
  • Concurrent malignancy. Study participants with a history of malignancy within the past 5 years prior to the Screening Visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been treated and is considered cured
  • History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
  • Known hypersensitivity to any components of bimekizumab or comparative drugs as stated in this protocol
  • Concomitant and prior medication restrictions
  • Myocardial infarction or stroke within the 6 months prior to the Screening Visit
  • Study participant has the presence of active suicidal ideation, or positive suicide behavior using the "Screening" version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
  • Presence of moderately severe major depression or severe major depression
  • Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Bimekizumab dosing regimen 1

Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.

Subjects will receive bimekizumab at pre-specified time-points.

Altri nomi:
  • UCB4940
Sperimentale: Bimekizumab dosing regimen 2

Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.

Subjects will receive bimekizumab at pre-specified time-points.

Altri nomi:
  • UCB4940
Sperimentale: Bimekizumab dosing regimen 3

Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.

Subjects will receive bimekizumab at pre-specified time-points.

Altri nomi:
  • UCB4940
Comparatore placebo: Placebo Group

Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.

Subjects will receive bimekizumab at pre-specified time-points.

Altri nomi:
  • UCB4940

Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.

Altri nomi:
  • PBO

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
Lasso di tempo: Week 16

HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model.

Week 16

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16
Lasso di tempo: Week 16

HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model.

Week 16
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
Lasso di tempo: Baseline, Week 16

The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data.

Baseline, Week 16
Absolute Change From Baseline in Worst Skin Pain Score at Week 16
Lasso di tempo: Baseline, Week 16

Absolute change from Baseline in Worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model.

Baseline, Week 16
Percentage of Participants Achieving Worst Skin Pain Response at Week 16
Lasso di tempo: Week 16

Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentage of participants shown do not account for model effects using logistic regression model.

Week 16
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
Lasso di tempo: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up [SFU] period).

From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study
Lasso di tempo: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).

From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study
Lasso di tempo: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported.

From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: UCB Cares, 001 844 599 2273

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

19 febbraio 2020

Completamento primario (Effettivo)

7 aprile 2022

Completamento dello studio (Effettivo)

19 febbraio 2023

Date di iscrizione allo studio

Primo inviato

23 gennaio 2020

Primo inviato che soddisfa i criteri di controllo qualità

23 gennaio 2020

Primo Inserito (Effettivo)

27 gennaio 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

26 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 ottobre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • HS0003
  • 2019-002550-23 (Numero EudraCT)
  • 2019 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Periodo di condivisione IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Criteri di accesso alla condivisione IPD

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .